Sanofi Consumer Healthcare India Limited

As of June 30, 2026, Sanofi Consumer Healthcare India Limited carries a market capitalization of 105.87B, placing it among publicly traded companies globally. Its enterprise value stands at 101.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sanofi Consumer Healthcare India Limited's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Sanofi Consumer Healthcare India Limited has 23.03M shares outstanding.

As of June 30, 2026, Sanofi Consumer Healthcare India Limited trades at a trailing price-to-earnings ratio of 39.80. The price-to-sales ratio is 11.15, and the price-to-book ratio stands at 30.43.

As of June 30, 2026, Sanofi Consumer Healthcare India Limited trades at an EV/EBITDA multiple of 28.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.78 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 101.16B versus a market cap of 105.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sanofi Consumer Healthcare India Limited maintains a current ratio of 2.03, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.98, indicating elevated leverage, while an interest coverage ratio of 176.45 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sanofi Consumer Healthcare India Limited posted a return on equity (ROE) of 87.95, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 76.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 47.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 81.80, useful for judging operating efficiency across full business cycles. The company generates approximately 16.00M in revenue per employee across its workforce of 593.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.83 indicates how many times Sanofi Consumer Healthcare India Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sanofi Consumer Healthcare India Limited recorded 912.00M in income tax expense. That works out to an effective tax rate of 25.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.57B, leaving 2.66B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sanofi Consumer Healthcare India Limited's stock has declined approximately 30.75% over the past 52 weeks. The 50-day moving average sits at 3,984.67, while the 200-day moving average is 4,364.37.

Over the twelve months ended June 30, 2026, Sanofi Consumer Healthcare India Limited generated 9.50B in revenue and converted that into 2.66B in net income, yielding earnings per share of 115.49. EBITDA reached 3.53B, while operating income came in at 3.40B.

As of June 30, 2026, Sanofi Consumer Healthcare India Limited holds 4.92B in cash and equivalents against 208.00M in total debt, resulting in a net debt position of -4.90B. Total book value stands at 3.48B, with working capital of 3.36B providing operational flexibility.

Over the twelve months ended June 30, 2026, Sanofi Consumer Healthcare India Limited posted a gross margin of 74.46, reflecting its pricing power and cost economics. The operating margin of 35.77 and net profit margin of 28.01 provide insight into operational efficiency.